ViOptix Revenue and Competitors
Estimated Revenue & Valuation
- ViOptix's estimated annual revenue is currently $1.3M per year.
- ViOptix's estimated revenue per employee is $84,000
Employee Data
- ViOptix has 15 Employees.
- ViOptix grew their employee count by 7% last year.
ViOptix Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $203M | 1014 | -20% | $65M | N/A |
#2 | $33.4M | 217 | 2% | N/A | N/A |
#3 | $45M | 299 | -4% | $102.6M | N/A |
#4 | $3.2M | 30 | -25% | $21.3M | N/A |
#5 | $34M | 226 | 0% | $42.9M | N/A |
#6 | $3.6M | 34 | -28% | $35M | N/A |
#7 | $0.8M | 10 | N/A | N/A | N/A |
#8 | $12.6M | 90 | -9% | N/A | N/A |
#9 | $17.4M | 124 | 0% | $96.4M | N/A |
#10 | $7.9M | 65 | 18% | $75.6M | N/A |
What Is ViOptix?
ViOptix has developed the proprietary breakthrough T.Ox Tissue Oximetry technology which enables non-invasive, direct, real-time measurement of local tissue oxygen saturation.The key benefit of the T.Ox technology is that it allows physicians, for the first time, to obtain accurate, real-time, direct measurement of tissue oxygen levels which enables them to assess tissue health “on the spotâ€. Applications of our platform technology, include but are not limited to: • Plastic surgery • Intraoperative and postoperative tissue oxygen saturation monitoring and determination of tissue viability • Estimation of wound healing potential • Peripheral Vascular Disease • Critical Care
keywords:N/AN/A
Total Funding
15
Number of Employees
$1.3M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ViOptix News
Global Cerebral and Tissue Oximetry Devices Market 2022 Latest Innovations and Outlook By Players Reflectance Medical, Spectros, ViOptix.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.3M | 15 | 275% | N/A |
#2 | $1.3M | 15 | -6% | N/A |
#3 | $1.3M | 15 | -12% | N/A |
#4 | $2.2M | 15 | N/A | N/A |
#5 | $1.3M | 15 | -25% | N/A |